• Corpus ID: 3249296

Topical cannabinoids in dermatology.

@article{Hashim2017TopicalCI,
  title={Topical cannabinoids in dermatology.},
  author={Peter W. Hashim and Joel L Cohen and David T Pompei and Gary Goldenberg},
  journal={Cutis},
  year={2017},
  volume={100 1},
  pages={
          50-52
        }
}
Topical cannabinoids are increasingly utilized by dermatology patients for a range of disorders; however, the acceptance of these over-the-counter products has far outpaced scientific investigation into their safety and efficacy. Here, we review the studies of topical cannabinoids in skin conditions and assess their current place in dermatology practice. 

Tables from this paper

Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single‐centre randomized evaluator‐blinded clinical and in vitro studies in normal skin
An increasing number of studies have investigated the adverse effect profile of oral cannabinoids; however, few studies have provided sufficient data on the tolerability of topical cannabinoids in
Novel cannabidiol aspartame combination treatment (JW‐100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double‐blinded placebo‐controlled interventional study
TLDR
Various studies have reported on cannabidiol’s effectiveness in relieving pain and easing inflammation while not presenting major health risks.
Cannabinoids: from pot to lab
TLDR
Some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, changes in their composition and forms of cannabis use, the concept of medical cannabis, and synthetic cannabinoids as new psychoactive substances (NPS) are reviewed.
A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson’s Disease and the Potential Role of Oral Cannabinoids
TLDR
The pathophysiological mechanisms and possible therapeutic role of oral cannabinoids in PD patients with SD are explored, and speculative mechanisms underlying the association of PD and SD are reviewed.
Endocannabinoid System Components: Overview and Tissue Distribution.
TLDR
The components and tissue distribution of this previously unknown but ubiquitous and complex ECS that is involved in almost all aspects of mammalian physiology and pathology are reviewed.
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model
TLDR
The effects of CBR agonists on skin inflammation, using acute and chronic inflammation animal models, are investigated.
Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis
TLDR
Cannabidiol (CBD) attenuates inflammation and pain without side‐effects, but CBD is hydrophobic and has poor oral bioavailability, so topical application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels.
Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia
TLDR
Topical therapy with cannabinoid receptor agonist seems likely to suppress local burning pain in herpes zoster patients and help reduce the burning pain transmitted by unmyelinated nerve fibers.
Anti‐inflammatory activity of topical THC in DNFB‐mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors
TLDR
The mechanism of the anti‐inflammatory activity of THC and the role of CB1 and CB2 receptors are investigated and related cannabinoids are considered for the treatment of inflammatory skin diseases.
A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis
TLDR
Daily treatment with topical 1 % CBD-cream may exert neuroprotective effects against EAE, diminishing clinical disease score, and suggest an interesting new profile of CBD that could lead to its introduction in the clinical management of MS and its associated symptoms at least in association with current conventional therapy.
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice
TLDR
The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
Cannabinoid–Opioid Interaction in Chronic Pain
TLDR
It is concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels, and may allow for opioid treatment at lower doses with fewer side effects.
Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
TLDR
Smoked cannabis was generally well tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV DSPN.
Low-dose vaporized cannabis significantly improves neuropathic pain.
Cannabis in painful HIV-associated sensory neuropathy
TLDR
Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy and the findings are comparable to oral drugs used for chronic Neuropathic pain.
...
1
2
...